Year Published
- (-) Remove 2008 filter 2008
- 2009 (1) Apply 2009 filter
- 2010 (3) Apply 2010 filter
- 2011 (4) Apply 2011 filter
- 2012 (11) Apply 2012 filter
- 2013 (5) Apply 2013 filter
- (-) Remove 2014 filter 2014
- (-) Remove 2015 filter 2015
- 2016 (2) Apply 2016 filter
- 2017 (5) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (1) Apply 2019 filter
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (1) Apply Data Analysis filter
- Literature Review (3) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (2) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (1) Apply LSMS & LSMS-ISA filter
- Other Datasets (0)
Current search
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Sustainable Agriculture & Rural Livelihoods filter Sustainable Agriculture & Rural Livelihoods
- (-) Remove 2015 filter 2015
- (-) Remove Global filter Global
- (-) Remove Market & Value Chain Analysis filter Market & Value Chain Analysis
- (-) Remove 2018 filter 2018
- (-) Remove 2008 filter 2008
- (-) Remove 2014 filter 2014
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
Cereal yield variability is influenced by initial conditions such as suitability of the farming system for cereal cultivation, current production quantities and yields, and zone-specific potential yields limited by water availability. However, exogenous factors such as national policies, climate, and international market conditions also impact farm-level yields directly or provide incentives or disincentives for farmers to intensify production. We conduct a selective literature review of policy-related drivers of maize yields in Ethiopia, Kenya, Malawi, Rwanda, Tanzania, and Uganda and pair the findings with FAOSTAT data on yield and productivity. This report presents our cumulative findings along with contextual evidence of the hypothesized drivers behind maize yield trends over the past 20 years for the focus countries.
The review consists of a summary of the emergence of agribusiness clusters, SEZs and incubators since 1965 (with a focus on smallholder agriculture-based economies in Latin America, Africa, and Asia), followed by a series of brief case studies of example programs with particular relevance for guiding proposed clusters/incubators in the countries of Ethiopia, Tanzania, Nigeria and the Eastern Indian states of Uttar Pradesh, Bihar, and Odisha. Summary conclusions draw upon published reports and primary analysis of case studies to highlight apparent determinants of success and failure in agribusiness investment clusters and incubators, including characteristics of the business environment (markets, policies) and characteristics of the organizational structure (clusters, accelerators) associated with positive smallholder outcomes.
The purpose of this analysis is to provide a measure of marketable surplus of maize in Tanzania. We proxy marketable surplus with national-level estimates of total maize sold, presumably the surplus for maize producing and consuming households. We also provide national level estimates of total maize produced and estimate “average prices” for Tanzania which allows this quantity to be expressed as an estimate of the value of marketable surplus. The analysis uses the Tanzanian National Panel Survey (TNPS) LSMS – ISA which is a nationally representative panel survey, for the years 2008/2009 and 2010/2011. A spreadsheet provides our estimates for different subsets of the sample and using different approaches to data cleaning and weighting. The total number of households for Tanzania was estimated with linear extrapolation based on the Tanzanian National Bureau of Statistics for the years 2002 and 2012. The weighted proportions of maize-producing and maize-selling households were multiplied to the national estimate of total households. This estimate of total Tanzanian maize-selling and maize-producing households was then multiplied by the average amount sold and by the average amount produced respectively to obtain national level estimates of total maize sold and total maize produced in 2009 and 2011.